Pyrazinamide is an important drug in the anti-tuberculosis drugs, anti-tuberculosis treatment is often used pyrazinamide, and the criteria for its discontinuation should be determined according to the chemotherapy program. It can be discontinued at the end of the 2-month intensive period for first-time patients and at the end of the 3-month intensive period for retreatment patients. Patients with multi-drug resistance need to stay on pyrazinamide for the entire course of treatment and discontinue it when they are cured. Adverse reactions to pyrazinamide can occur in the following areas: 1, hepatic injury; 2, secondary gout; 3, gastrointestinal reactions and allergic reactions. If serious adverse reactions occur, such as severe hepatic injury, severe allergic reactions, or severe gastrointestinal reactions, prompt discontinuation is required.